Tango Biosciences, Inc. is a biotechnology company that specializes in developing pairs of recombinant antibodies for use in immunoassays. Pairs of antibodies to target proteins will be generated through a phage-display process invented at UIC and termed 'Megaprimer Shuffled Tandem Affinity Reagents' (MegaSTAR). Our approach offers the opportunity to create unique reagents quickly and in a streamlined manner. As these antibodies are recombinant in nature, their DNA sequence is known, which allows renewability and engineering, unlike traditional polyclonal and monoclonal antibodies. Immunoassays are the cornerstone of most clinical assays, and the immunoassay market is expected to grow globally to $24B by 2019. Tango Biosciences discovers and generates pairs of high-quality recombinant antibodies that can be used in immunoassays to detect and quantify biomarkers of human disease. These reagents are generated without animals, and are renewable and amenable to protein engineering.
Tango Biosciences is presenting as part of the NIH Innovation Zone.